| Senior Doc Indiana, Pc | |
|
2592 N Santiago Blvd Orange CA 92867-1862 | |
| (855) 434-7763 | |
| (949) 281-5550 |
| Full Name | Senior Doc Indiana, Pc |
|---|---|
| Speciality | Family Medicine |
| Location | 2592 N Santiago Blvd, Orange, California |
| Authorized Official Name and Position | Angelica Leyla Soto (CREDENTIALING SPECIALIST) |
| Authorized Official Contact | 8554347763 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Senior Doc Indiana, Pc 2592 N Santiago Blvd Orange CA 92867-1862 Ph: (855) 434-7763 | Senior Doc Indiana, Pc 2592 N Santiago Blvd Orange CA 92867-1862 Ph: (855) 434-7763 |
| NPI Number | 1710748397 |
|---|---|
| Provider Enumeration Date | 01/19/2024 |
| Last Update Date | 01/19/2024 |
| Medicare PECOS PAC ID | 2466897848 |
|---|---|
| Medicare Enrollment ID | O20240226000319 |
News Archive
Paladin Labs Inc. and Somaxon Pharmaceuticals, Inc. today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.
Researchers from NYU Langone Medical Center's Departments of Orthopaedic Surgery and Radiology found that advanced MRI techniques can be used to detect subtle changes in joint cartilage microstructure - and provide physicians a diagnostic tool for finding key markers of early osteoarthritis.
Good news for public health: Bioengineering researchers from the EPFL in Lausanne, Switzerland, have developed and patented a nanoparticle that can deliver vaccines more effectively, with fewer side effects, and at a fraction of the cost of current vaccine technologies.
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710748397 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | John M Geiss |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1053651497 PECOS PAC ID: 5890933071 Enrollment ID: I20240313000359 |
News Archive
Paladin Labs Inc. and Somaxon Pharmaceuticals, Inc. today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.
Researchers from NYU Langone Medical Center's Departments of Orthopaedic Surgery and Radiology found that advanced MRI techniques can be used to detect subtle changes in joint cartilage microstructure - and provide physicians a diagnostic tool for finding key markers of early osteoarthritis.
Good news for public health: Bioengineering researchers from the EPFL in Lausanne, Switzerland, have developed and patented a nanoparticle that can deliver vaccines more effectively, with fewer side effects, and at a fraction of the cost of current vaccine technologies.
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test.
› Verified 6 days ago
News Archive
Paladin Labs Inc. and Somaxon Pharmaceuticals, Inc. today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.
Researchers from NYU Langone Medical Center's Departments of Orthopaedic Surgery and Radiology found that advanced MRI techniques can be used to detect subtle changes in joint cartilage microstructure - and provide physicians a diagnostic tool for finding key markers of early osteoarthritis.
Good news for public health: Bioengineering researchers from the EPFL in Lausanne, Switzerland, have developed and patented a nanoparticle that can deliver vaccines more effectively, with fewer side effects, and at a fraction of the cost of current vaccine technologies.
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test.
› Verified 6 days ago
Zhihong Acupuncture Clinic Co Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2950 N Glassell St,, Suite B, Orange, CA 92865 Phone: 714-858-0952 Fax: 714-998-6499 | |
Senior Doc Wyoming, P.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2592 N Santiago Blvd, Orange, CA 92867 Phone: 855-434-7763 | |
Regenerative Medical Group Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 615 E Chapman Ave, Orange, CA 92866 Phone: 714-639-4012 Fax: 714-639-4018 | |
Trucare Health Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1234 W Chapman Ave, Ste# 101, Orange, CA 92868 Phone: 714-883-1604 | |
Western Hospitalists Group Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 655 S Main St, Ste. 306, Orange, CA 92868 Phone: 714-397-0844 | |
Geiss Med Nevada Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2592 N Santiago Blvd, Orange, CA 92867 Phone: 855-434-7763 | |
Coastal Dream Docs Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2860 N Santiago Blvd, Ste 110, Orange, CA 92867 Phone: 949-645-0000 Fax: 949-645-0003 |